]>
IRCT2015062722934N1 IRCT 2015-07-24 Vice Chancellor for research of Tehran University of Medical Sciences Investigate the effects of Pomegranate Extract Supplementation on Inflammation in Overweight and Obese Individuals Investigate the effects of Pomegranate Extract Supplementation on Inflammation in Overweight and Obese Individuals 2014-03-20 anticipated 48 Complete https://irct.ir/trial/19674 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Other design features: A stratified randomized permuted block (with block size randomly varied between 2 or 4) was generated by a biostatistician. N/A Overweight and obesity. Intervention 1: Intervention group: In the intervention group 1000 mg pomegranate extract through two capsules one of each had 500 mg was consumed daily for 30 days. Intervention 2: Control group: In the control group, 1000 mg identical placebo made by pure crystalline was consumed daily through two capsules one of each had 500 mg placebo for 30 days.
public Dr. Ahmad Saedi
Enqelab Street
Tehran Iran (Islamic Republic of) +98 21 8895 5805 a_saedi@tums.ac.ir Tehran University of Medical Sciences scientific Dr. Ahmad Saedi
Enqelab Sreet
Tehran Iran (Islamic Republic of) +98 21 8895 5805 a_saedi@tums.ac.ir Tehran University of Medical Sciences Iran (Islamic Republic of) Inclusion Criteria: Willingness to participation; Between the age 30-60 years old and Having a BMI within the range 25-40 kgm2; does not have a history of use of any dietary supplements within 3 months prior to the study; does not smoking or alcohol consumption; does not take any cholesterol; triglyceride as well as blood lowering medicine; does not suffer from any acute condition which needs treatment; does not suffer from metabolic stress, infection or inflammation; does not suffer from abnormal liver or kidney function; without any history of heart disease; does not take estrogen and progesterone; does not suffer from poly cyctic ovarian syndrome; not be pregnant or does not lactating. Exclusion criteria:; meet any aforementioned condition which can exclude the participants from the study ; present any changes in the diet or physical activity. 30 years 60 years Both E66.9 Simple obesity NOS Other Placebo Intervention group: In the intervention group 1000 mg pomegranate extract through two capsules one of each had 500 mg was consumed daily for 30 days. Control group: In the control group, 1000 mg identical placebo made by pure crystalline was consumed daily through two capsules one of each had 500 mg placebo for 30 days. IL-6. Timepoint: 30 days. Method of measurement: IL-6 was measured by ELISA kits (BioCore, Germany). MDA. Timepoint: 30 days. Method of measurement: IL-6 was measured by ELISA kits (BioCore, Germany). Hs-CRP. Timepoint: 30 days. Method of measurement: ELISA method using using commercial ELISA kit (Biochem, Ontario, Canada). Glucose. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran). Cholestrol. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran). HDL-C. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran). LDL-C. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran). Insulin. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran). Vice Chancellor for research of Tehran University of Medical Sciences Approved 2015-02-01 Ethics committee of Tehran University of Medical Sciences Enqelab Street Tehran Iran (Islamic Republic of)